DHA molecular active probe as well as preparation method and application thereof
By covalently combining DHA with fluorescein or biotin, the high-purity DHA molecular active probe was solved, and the problem of unclear distribution and metabolic pathways in DHA organisms was realized, real-time monitoring and research of DHA biological activity was simplified, and the preparation was simplified. and has biological activity to prevent non-alcoholic fatty liver.
Patent Information
- Application Number
- CN202411128028.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-16
- Publication Date
- 2024-11-26
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The specific targets, mechanisms of action, tissue distribution and metabolic pathways of DHA in organisms have not been fully understood, and it is difficult to achieve real-time monitoring and research on its biological activities.
Develop a DHA molecular active probe that prepares a high-purity DHA-P probe by covalently binding DHA with reporter groups such as fluorescein or biotin and a series of purification steps for real-time use in vitro or in vivo Track the distribution and metabolism of DHA.
Real-time monitoring of DHA biological activity is achieved, an in-depth understanding of its mechanism of action is improved, the efficiency of pharmacological research is improved, the preparation method is simplified, the product is purified, and the biological activity is to prevent non-alcoholic fatty liver.
Smart Images

Figure CN119019255A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of molecular probes, and in particular to a DHA molecular activity probe and a preparation method and application thereof. Background Art
[0002] DHA (docosahexaenoic acid) is an ω-3 polyunsaturated fatty acid that has many benefits for human health, especially in brain development and vision protection. In recent years, the application of DHA in the medical field has increased, especially in cancer diagnosis and treatment, cardiovascular and cerebrovascular disease prevention and other aspects of the potential is gradually emerging. However, the specific target of DHA in the body, mechanism of action, tissue distribution and metabolic pathway are not yet fully understood. Therefore, it is necessary to develop a DHA molecular probe to achieve real-time monitoring and research of its biological activity. Summary of the invention
[0003] To solve the above problems, the present invention provides a DHA molecular activity probe and a preparation method and application thereof. The probe comprises a reporter group such as fluorescein or biotin labeled on the DHA molecule, which can be used to track the distribution and metabolism of DHA in real time in vitro or in vivo. DHA is covalently bound to the reporter group through a chemical reaction, and unreacted reagents and by-products are removed through a series of purification steps to ensure the purity and stability of the probe.
[0004] To achieve the above object, the present invention provides a method for preparing a DHA molecular activity probe, comprising the following steps:
[0005] S1, adding DHA, alkynyl alcohol and condensing agent into an organic solvent in sequence and fully dissolving them;
[0006] S2, stirring the solution obtained in step S1 at 20-30° C. in the dark for 12-24 h, and concentrating the organic phase in vacuo;
[0007] S3. Purify the concentrate obtained in step S2 by solid phase extraction column chromatography to obtain DHA molecular activity probe DHA-P.
[0008] Preferably, the condensing agent is one or more of 4-dimethylaminopyridine, 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride, 1-hydroxybenzotriazole, dicyclohexylcarbodiimide (DCC), and 1,3-diisopropylcarbodiimide.
[0009] Preferably, the molar ratio of DHA to the condensing agent is 1.5-10:1, and the molar ratio of DHA to the alkynyl alcohol is 1:1.
[0010] A DHA molecular activity probe prepared by the above-mentioned preparation method has the following structure:
[0011]
[0012] The present invention provides a DHA molecular activity probe and a preparation method and application thereof, which has the following characteristics:
[0013] Beneficial effects:
[0014] (1) DHA molecular activity probes can be used as bio-orthogonal labeling probes, especially for labeling DHA, to study the pharmacological mechanisms of DHA in neuroprotection, brain development, prevention of cardiovascular and cerebrovascular diseases, cancer diagnosis, distribution of DHA in organisms and metabolic pathways, explore DHA action targets, help to gain a deeper understanding of the mechanism of action of DHA, and better develop and utilize DHA;
[0015] (2) The DHA active probe prepared by the method of the present invention has high purity, with a purity of ≥98%, meeting the pharmacopoeia standard;
[0016] (3) The present invention successfully prepares a DHA molecular active probe by a one-step method, which greatly simplifies the synthesis steps, and the required synthesis conditions are mild and the synthesis rate is high;
[0017] (4) The DHA molecular probe prepared by the present invention has high biological activity and has certain effects in preventing non-alcoholic fatty liver disease, and can be directly used in the preparation of drugs for preventing non-alcoholic fatty liver disease.
[0018] The technical solution of the present invention is further described in detail below through the accompanying drawings and embodiments. BRIEF DESCRIPTION OF THE DRAWINGS
[0019] Figure 1 The hydrogen nuclear magnetic resonance spectrum of DHA-P in Example 1;
[0020] Figure 2 DHA-P in Example 1 13 C NMR;
[0021] Figure 3 The DHA / DHA-P Oil Red O staining diagram in Example 2; wherein, a and b are the states before HepG2 cell modeling, c and d are the states of 0.6 mM OA modeling simulating non-alcoholic fatty liver disease, e is the state of DHA and 0.6 mM OA modeling simulating non-alcoholic fatty liver disease, and f is the state of DHA-P and 0.6 mM OA modeling simulating non-alcoholic fatty liver disease;
[0022] Figure 4 This is the quantitative statistical result of the DHA / DHA-P Oil Red O staining results in Example 2. DETAILED DESCRIPTION
[0023] In order to make the purpose, technical scheme and advantages disclosed in the embodiments of the present invention more clearly understood, the embodiments of the present invention are further described in detail below in conjunction with the accompanying drawings and embodiments. It should be understood that the specific embodiments described herein are only used to explain the embodiments of the present invention and are not intended to limit the embodiments of the present invention. Based on the embodiments in this application, all other embodiments obtained by ordinary technicians in this field without making creative work are within the scope of protection of this application.
[0024] Embodiment 1
[0025] 0.20mmol DHA (substrate), 0.40mmol 4-dimethylaminopyridine DMAP (condensing agent), 0.30mmol 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride EDCI (condensing agent), 0.30mmol 1-hydroxybenzotriazole HOBT (condensing agent), and 0.20mmol 4-Pentyn-1-ol (substrate) were dissolved in dichloromethane and reacted at 25°C for 20h to obtain a mixed solution.
[0026] The obtained mixed solution was concentrated by vacuum rotary evaporation and purified by chromatography column (petroleum ether: ethyl acetate = 4:1) to obtain DHA molecular probe (DHA-P) with a product yield of 72%.
[0027] The reaction formula is as follows:
[0028]
[0029] The H NMR spectrum of the prepared DHA-P is as follows Figure 1 As shown, 1 H NMR (500MHz, CDCl3) δ5.50-5.21(m,12H),4.18(t,J=6.3Hz,2H),2.87-2.80(m,10H),2.41-2.35( m,4H),2.29(td,J=7.1,2.7Hz,2H),2.11-2.04(m,2H),1.89-1.82(m,2H),0.97(t,J=7.5Hz,3H).
[0030] The prepared DHA-P 13 C NMR images Figure 2 As shown, 13C NMR (126MHz, CDCl3) δ173.03,132.03,129.32,128.57,128.27,128.23,128.12,128.07,127.89 ,127.02,82.99,69.01,62.91,34.17,27.57,25.64,25.60,25.55,22.79,20.57,15.22,14.28.
[0031] Embodiment 2
[0032] Comparison of the effects of DHA and DHA probe on lipid accumulation in HepG2 cells
[0033] like Figure 3 As shown, untreated HepG2 cells were used as the control group, and the treatment groups included: HepG2 cells treated with 0.6 mM oleic acid (OA) for 24 h, and HepG2 cells treated with 0.6 mM oleic acid (OA) and 25 μM DHA or DHA-P for 24 h.
[0034] The control group and the treated group were stained using the following methods:
[0035] (1) Slowly aspirate the cell culture medium and wash once with PBS;
[0036] (2) Add 4% paraformaldehyde fixative for 10 min and rinse twice with PBS;
[0037] (3) Add an appropriate amount of staining solution to cover the cells for 20 seconds, then remove the staining solution, add an appropriate amount of Oil Red O staining working solution, and stain for 20 minutes;
[0038] (4) Remove the Oil Red O staining solution, add an appropriate amount of staining wash solution, let stand for 30 seconds, then remove the staining wash solution and wash with PBS for 20 seconds;
[0039] (5) Add an appropriate amount of PBS to evenly cover the cells and observe and take pictures under a microscope.
[0040] The OA model can simulate the state of non-alcoholic fatty liver disease, and Oil Red O dye can specifically dye neutral lipids such as lipid droplets in cells or triglycerides in tissues red or orange-red.
[0041] Depend on Figure 3It can be seen that a and b are the states before HepG2 cells were modeled, c and d are the states of non-alcoholic fatty liver simulated by 0.6 mM OA modeling, e is the state of non-alcoholic fatty liver simulated by DHA and 0.6 mM OA modeling, and f is the state of non-alcoholic fatty liver simulated by DHA-P and 0.6 mM OA modeling. Compared with the 0.6 mM OA treatment group, 25 μM DHA or DHA-P can significantly reduce the lipid accumulation of HepG2 cells.
[0042] Figure 4 is the quantitative statistical result of Oil Red O staining, Figure 4 It can be seen that 0.6 mM OA can significantly induce lipid accumulation in HepG2, while preventive administration of 25 μM DHA / DHA-P can reduce the lipid accumulation level by 50% / 25%, respectively.
[0043] Embodiment 3
[0044] 0.20 mmol DHA (substrate), 0.40 mmol 4-dimethylaminopyridine DMAP (condensing agent), and 0.20 mmol 4-Pentyn-1-ol (substrate) were dissolved in dichloromethane, and reacted at 25° C. for 20 h to obtain a mixed solution.
[0045] The obtained mixed solution was concentrated by vacuum rotary evaporation and purified by chromatography column to obtain DHA molecular probe (DHA-P), and the product yield was 51%. Compared with Example 1, the concentration and type of condensing agent significantly affected the product yield, and low concentration or single condensing agent type greatly reduced the yield of molecular probe.
[0046] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention rather than to limit it. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that they can still modify or replace the technical solution of the present invention with equivalents, and these modifications or equivalent replacements cannot cause the modified technical solution to deviate from the spirit and scope of the technical solution of the present invention.
Claims
1. A method for preparing a DHA molecular activity probe, It is characterized in that The steps include: S1, adding DHA, alkynyl alcohol, catalyst and condensing agent into an organic solvent in sequence and fully dissolving them; S2, stirring the solution obtained in step S1 at 20-30° C. in the dark for 12-24 h, and concentrating the organic phase in vacuo; S3. Purify the concentrate obtained in step S2 by solid phase extraction column chromatography to obtain DHA molecular activity probe DHA-P.
2. A method for preparing a DHA molecular activity probe according to claim 1, Features: The condensing agent is one or more of 4-dimethylaminopyridine, 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride, 1-hydroxybenzotriazole, dicyclohexylcarbodiimide (DCC), and 1,3-diisopropylcarbodiimide.
3. The method for preparing a DHA molecular activity probe according to claim 1, Features: The molar ratio of DHA to the condensing agent is 1.5-10:1, and the molar ratio of DHA to the alkynyl alcohol is 1:
1.
4. A DHA molecular activity probe prepared by the preparation method according to any one of claims 1 to 3, It is characterized in that Has the following structure:
5. Use of the DHA molecular activity probe as claimed in claim 4 in monitoring and studying the biological activity of DHA molecules.
6. Use of the DHA molecular activity probe as claimed in claim 4 in the preparation of a drug for preventing non-alcoholic fatty liver disease.
Citation Information
Patent Citations
Fatty acid analogues, i.e. dha derivatives for uses as a medicament
CN103058867A
Preparation method of inorganic hybrid nanometer phase change energy storage capsule
CN105289436A
Fatty acid derivatives for treating non-alcoholic steatohepatitis
CN111712240A
Near-infrared fluorescence labeled fatty acid and preparation method thereof
CN113527347A
Novel compounds
US20070088170A1
